219 related articles for article (PubMed ID: 17379933)
21. Thailand diabetes registry project: prevalence, characteristics and treatment of patients with diabetic nephropathy.
Ngarmukos C; Bunnag P; Kosachunhanun N; Krittiyawong S; Leelawatana R; Prathipanawatr T; Plengvidhya N; Benjasuratwong Y; Suwanwalaikorn S; Deerochanawong C; Chetthakul T; Mongkolsomlit S; Rawdaree P
J Med Assoc Thai; 2006 Aug; 89 Suppl 1():S37-42. PubMed ID: 17715832
[TBL] [Abstract][Full Text] [Related]
22. Hyperkalaemia in a patient with Graves' disease.
Ng CW; Chan NN; So WY; Chan WB; Chow CC
Int J Clin Pract; 2003 Sep; 57(7):631-2. PubMed ID: 14529068
[TBL] [Abstract][Full Text] [Related]
23. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
24. Angiotensin receptor blockers do not have an advantage over angiotensin-converting inhibitors [corrected].
Harman-Boehm I
Isr Med Assoc J; 2004 May; 6(5):296-8. PubMed ID: 15151373
[No Abstract] [Full Text] [Related]
25. Severe hyperkalaemia after cotrimoxazole administration in a patient with hyporeninaemic hypoaldosteronism.
Elisaf M; Terrovitou C; Tomos P; Siamopoulos KC
Nephrol Dial Transplant; 1997 Jun; 12(6):1254-5. PubMed ID: 9198062
[No Abstract] [Full Text] [Related]
26. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus.
Fogari R; Derosa G; Zoppi A; Rinaldi A; Preti P; Lazzari P; Mugellini A
Hypertens Res; 2008 Jan; 31(1):43-50. PubMed ID: 18360017
[TBL] [Abstract][Full Text] [Related]
27. Hyperkalaemia with cyclooxygenase-2 inhibition and hypoaldosteronism.
Lam Q; Schneider HG
Intern Med J; 2005 Sep; 35(9):572-3. PubMed ID: 16105165
[No Abstract] [Full Text] [Related]
28. Clinical inquiries. Do ACE inhibitors prevent nephropathy in type 2 diabetes without proteinuria?
Sferra L; Kelsberg G; Dodson S; Saseen J
J Fam Pract; 2004 Jan; 53(1):68-9. PubMed ID: 14709273
[No Abstract] [Full Text] [Related]
29. FPIN's clinical inquiries. Angiotensin blockade in patients with diabetic nephropathy.
Jimenez J; Safranek S; Viera AJ
Am Fam Physician; 2007 Aug; 76(3):423-4. PubMed ID: 17708144
[No Abstract] [Full Text] [Related]
30. Treating hypertension in the patient with overt diabetic nephropathy.
Lewis EJ
Semin Nephrol; 2007 Mar; 27(2):182-94. PubMed ID: 17418687
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis.
Weidmann P; Schneider M; Böhlen L
Nephrol Dial Transplant; 1995 Oct; 10 Suppl 9():39-45. PubMed ID: 8643207
[No Abstract] [Full Text] [Related]
32. Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacological blockade of the renin-angiotensin system.
Rodby RA
Nephrol Dial Transplant; 1997 Jun; 12(6):1095-6. PubMed ID: 9198032
[No Abstract] [Full Text] [Related]
33. Reversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism.
Bonnet F; Thivolet CH
Diabetes Care; 1996 Jul; 19(7):781. PubMed ID: 8799646
[No Abstract] [Full Text] [Related]
34. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus.
Agha A; Bashir K; Anwar E
Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953
[TBL] [Abstract][Full Text] [Related]
35. Determinants of progression from microalbuminuria to proteinuria in patients who have type 1 diabetes and are treated with angiotensin-converting enzyme inhibitors.
Ficociello LH; Perkins BA; Silva KH; Finkelstein DM; Ignatowska-Switalska H; Gaciong Z; Cupples LA; Aschengrau A; Warram JH; Krolewski AS
Clin J Am Soc Nephrol; 2007 May; 2(3):461-9. PubMed ID: 17699452
[TBL] [Abstract][Full Text] [Related]
36. Aliskiren combined with losartan in diabetes and nephropathy.
Lindner T
N Engl J Med; 2008 Sep; 359(10):1068-9; author reply 1069-70. PubMed ID: 18777612
[No Abstract] [Full Text] [Related]
37. [Hypertension therapy for type 2 diabetics].
Bönner G
MMW Fortschr Med; 2007 Jun; 149(23):45, 47-8. PubMed ID: 18062579
[No Abstract] [Full Text] [Related]
38. [Revised guidelines for antihypertensive treatment. What is relevant for the general practitioner?].
Zidek W
MMW Fortschr Med; 2004 Jan; 146(1-2):37-8. PubMed ID: 18437867
[No Abstract] [Full Text] [Related]
39. Life-threatening hyperkalaemia caused by angiotensin-converting enzyme-inhibitor and diuretics.
Odawara M; Asano M; Yamashita K
Diabet Med; 1997 Feb; 14(2):169-70. PubMed ID: 9047098
[No Abstract] [Full Text] [Related]
40. A randomized trial of a 6-week course of celecoxib on proteinuria in diabetic kidney disease.
Sinsakul M; Sika M; Rodby R; Middleton J; Shyr Y; Chen H; Han E; Lehrich R; Clyne S; Schulman G; Harris R; Lewis J
Am J Kidney Dis; 2007 Dec; 50(6):946-51. PubMed ID: 18037095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
